Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: A prospective study

Clinical Nephrology

Volumn 68, Issue 5, 2007, Pages 302-307

  Schneider, M ^a   Thomas, K ^a   Liefeldt, L ^a   Kindgen Milles, D ^b   Peters, H ^a   Neumayer, H H ^a   Morgera, Stanislao ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Acid base status; Citrate anticoagulation; Electrolytes; Intermittent hemodialysis; Renal failure

Indexed keywords

CITRATE TRISODIUM;

ACID BASE BALANCE; ACUTE KIDNEY FAILURE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG SAFETY; ELECTROLYTE BALANCE; FEMALE; HEART HEMODYNAMICS; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERNATREMIA; HYPOCALCEMIA; MALE; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; TREATMENT DURATION;

EID: 35748963862     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68302     Document Type: Article

References (17)

1. Apsner R, Druml W. More on anticoagulation for continuous hemofiltration. N Engl J Med. 1998; 338: 131-132.
2. Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001; 89: 233-236.
3. De Vos J, Hombrouckx R. Citrate anticoagulation and adverse events. Edtna Erca J. 2003; 29: 112-113.
4. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intens Care Med. 2002; 28: 1419-1425.
5. Gangji AS, Rabbat CG, Margetts PJ. Benefit of continuous renal replacement therapy in subgroups of acutely ill patients: a retrospective analysis. Clin Nephrol. 2005; 63: 267-275.
6. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis. 1987; 9: 235-236.
7. Kes P. Slow continuous renal replacement therapies: an update. Acta Med Croatica. 2000; 54: 69-84.
8. Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol. 1991; 2: 961-975.
9. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intens Care Med. 2004; 30: 260-265.
10. Morgera S, Haase M, Ruckert M, Krieg H, Kastrup M, Krausch D, Vargas-Hein O, Zuckermann-Becker H, Peters H, Pohlmeier R, Neumayer HH. Regional Citrate anticoagulation in continuous hemodialysis - acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract. 2005; 101: c211-c219.
11. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004; 97: 131-136.
12. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999; 55: 1991-1997.
13. Remuzzi G. Bleeding in renal failure. Lancet. 1988; 1: 1205-1208.
14. Ricci Z, Ronco C, Bachetoni A, D'Amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care. 2006; 10: R67.
15. Shulman RI, Singer M, Rock J. Keeping the circuit open: lessons from the lab. Blood Purif. 2002; 20: 275-281.
16. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Acute renal failure in critically ill patients - a multinational, multicenter study. J Am Med Assoc. 2005; 294: 813-818.
17. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int. 1993; Suppl 41: 237-244.